Literature DB >> 28782462

Concentrations of CTX I, CTX II, DPD, and PYD in the urine as a biomarker for the diagnosis of temporomandibular joint osteoarthritis: A preliminary study.

Soo-Min Ok1, Seung-Min Lee2, Hae Ryoun Park3, Sung-Hee Jeong1, Ching-Chang Ko4, Yong-Il Kim2,5.   

Abstract

OBJECTIVES: The aim of this study was to identify a marker for temporomandibular joint (TMJ) osteoarthritis (OA) diagnosis by comparing the concentrations of urinary pyridinoline (PYD), deoxypyridinoline (DPD), and C-terminal telopeptides type I collagen (CTX-I), and CTX-II of TMJ OA patients with those of a non-symptomatic group.
METHODS: PYD, DPD, CTX-I, and CTX-II concentrations in the urine of 36 non-symptomatic subjects and 31 TMJ OA subjects were analyzed.
RESULTS: The differences for only PYD and DPD were significant. In ROC analysis, PYD and DPD showed higher sensitivity and specificity than CTX-I and CTX-II. PYD and DPD concentrations in urine were significantly increased in TMJ OA patients and can therefore be used as a biomarker in the supplementary clinical diagnosis of TMJ OA. DISCUSSION: The findings suggest that measurement of their concentration can be a supplementary method for clinical diagnosis of TMJ OA.

Entities:  

Keywords:  Temporomandibular joint; biomarker; erosion; osteoarthritis; urine

Mesh:

Substances:

Year:  2017        PMID: 28782462      PMCID: PMC5814361          DOI: 10.1080/08869634.2017.1361624

Source DB:  PubMed          Journal:  Cranio        ISSN: 0886-9634            Impact factor:   2.020


  19 in total

1.  Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†.

Authors:  Eric Schiffman; Richard Ohrbach; Edmond Truelove; John Look; Gary Anderson; Jean-Paul Goulet; Thomas List; Peter Svensson; Yoly Gonzalez; Frank Lobbezoo; Ambra Michelotti; Sharon L Brooks; Werner Ceusters; Mark Drangsholt; Dominik Ettlin; Charly Gaul; Louis J Goldberg; Jennifer A Haythornthwaite; Lars Hollender; Rigmor Jensen; Mike T John; Antoon De Laat; Reny de Leeuw; William Maixner; Marylee van der Meulen; Greg M Murray; Donald R Nixdorf; Sandro Palla; Arne Petersson; Paul Pionchon; Barry Smith; Corine M Visscher; Joanna Zakrzewska; Samuel F Dworkin
Journal:  J Oral Facial Pain Headache       Date:  2014

2.  Receiver operating characteristic analysis of urinary pyridinium cross-links in arthritis.

Authors:  M Takahashi; K Kushida; T Inoue
Journal:  Br J Rheumatol       Date:  1995-08

3.  Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation.

Authors:  S M Krane; F G Kantrowitz; M Byrne; S R Pinnell; F R Singer
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

4.  A new marker for osteoarthritis: cross-sectional and longitudinal approach.

Authors:  M Reijman; J M W Hazes; S M A Bierma-Zeinstra; B W Koes; S Christgau; C Christiansen; A G Uitterlinden; H A P Pols
Journal:  Arthritis Rheum       Date:  2004-08

5.  Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis.

Authors:  C Astbury; H A Bird; A M McLaren; S P Robins
Journal:  Br J Rheumatol       Date:  1994-01

6.  Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared.

Authors:  P Bettica; L Moro; S P Robins; A K Taylor; J Talbot; F R Singer; D J Baylink
Journal:  Clin Chem       Date:  1992-11       Impact factor: 8.327

Review 7.  Tissue responses to degenerative changes in the temporomandibular joint: a review.

Authors:  B Stegenga; L G de Bont; G Boering; J D van Willigen
Journal:  J Oral Maxillofac Surg       Date:  1991-10       Impact factor: 1.895

8.  Utility of urinary pyridinoline and deoxypyridinoline ratio for diagnosis of osteoarthritis at temporomandibular joint.

Authors:  K Tanimoto; S Ohno; M Imada; K Honda; M Ohno-Nakahara; S Kapila; K Tanne
Journal:  J Oral Pathol Med       Date:  2004-04       Impact factor: 4.253

9.  Alteration of cartilage degeneration and inflammation markers in temporomandibular joint osteoarthritis occurs proportionally.

Authors:  Lukas M Vos; Roel Kuijer; James J R Huddleston Slater; Boudewijn Stegenga
Journal:  J Oral Maxillofac Surg       Date:  2013-08-08       Impact factor: 1.895

10.  TMJ imaging by CBCT: Current scenario.

Authors:  Bhuvana Krishnamoorthy; Ns Mamatha; Vinod Ar Kumar
Journal:  Ann Maxillofac Surg       Date:  2013-01
View more
  6 in total

1.  [Urinary long non-coding RNA H19 may serve as a biomarker for early diagnosis of acute intestinal necrosis].

Authors:  Yulei Dai; Lubin Yan; Jieling Fan; Qi Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

2.  Bone mineral density, bone microstructure, and bone turnover markers in females with temporomandibular joint osteoarthritis.

Authors:  Seok Woo Hong; Jeong-Hyun Kang
Journal:  Clin Oral Investig       Date:  2021-04-16       Impact factor: 3.573

Review 3.  C-Terminal Cross-Linked Telopeptides of Type II Collagen as Biomarker for Radiological Knee Osteoarthritis: A Meta-Analysis.

Authors:  HongBin Cheng; Baoxi Hao; Jingtao Sun; Mingxi Yin
Journal:  Cartilage       Date:  2018-09-15       Impact factor: 4.634

4.  Extracellular matrix turnover and inflammation in chemically-induced TMJ arthritis mouse models.

Authors:  Mallory Morel; Angela Ruscitto; Serhiy Pylawka; Gwendolyn Reeve; Mildred C Embree
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

Review 5.  Biomarkers for Temporomandibular Disorders: Current Status and Future Directions.

Authors:  Abdalwhab Zwiri; Mohammad A I Al-Hatamleh; Wan Muhamad Amir W Ahmad; Jawaad Ahmed Asif; Suan Phaik Khoo; Adam Husein; Zuryati Ab-Ghani; Nur Karyatee Kassim
Journal:  Diagnostics (Basel)       Date:  2020-05-15

Review 6.  Mass Spectrometry Imaging as a Potential Tool to Investigate Human Osteoarthritis at the Tissue Level.

Authors:  Yea-Rin Lee; Matthew T Briggs; Mark R Condina; Hamish Puddy; Paul H Anderson; Peter Hoffmann; Julia S Kuliwaba
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.